Jason Shoush

Jason Shoush

Auto-generated profile, based on publicly available information

Jason Shoush

Institute for Immunology, Perelman School of Medicine, University of Pennsylvania 2 , Philadelphia, PA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247

30 September 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
IFIan W. Folkert
Ian W. Folkert
WAWilliam A. Molina Arocho
William A. Molina Arocho
TTTsun Ki Jerrick To
Tsun Ki Jerrick To
SDSamir Devalaraja
Samir Devalaraja
IMIrene S. Molina
Irene S. Molina
MHMalay Haldar
Malay Haldar
We define a subset of macrophages in the tumor microenvironment characterized by high intracellular iron and enrichment of heme and iron metabolism genes. These iron-rich tumor-associated macrophages (iTAMs) supported angiogenesis and immunosuppression in the tumor microenvironment and were conserved between mice and humans. iTAMs comprise two additional subsets based on gene expression profile and location—perivascular (pviTAM) and stromal (stiTAM). We identified the endothelin receptor type B (Ednrb) as a specific marker of iTAMs and found myeloid-specific deletion of Ednrb to reduce tumor growth and vascular density. Further studies identified the transcription factor Bach1 as a repressor of the iTAM transcriptional program, including Ednrb expression. Heme is a known inhibitor of Bach1, and, correspondingly, heme exposure induced Ednrb and iTAM signature genes in macrophages. Thus, iTAMs are a distinct macrophage subset regulated by the transcription factor Bach1 and characterized by Ednrb-mediated immunosuppressive and angiogenic functions.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
DGDavid Shihong Gao
David Shihong Gao
YLYang Li
Yang Li
JSJason Shoush
Jason Shoush
RSRunzi Sun
Runzi Sun
BLBinfeng Lu
Binfeng Lu
Recent studies suggest p53 contributes to poor survival in the context of immune checkpoint blockade (ICB). Mutations to p53 significantly improve the response rate to PD-1 ICB in lung cancer patients. Tumor-derived IL-33 is required for the anti-tumor immune response and efficacy of ICB. However, the relationship between p53 and IL-33 during ICB is unknown. In this study, we characterize the role of the p53/IL-33 axis in regulating the response of the tumor microenvironment to ICB. We use CRISPR-Cas9 to delete Trp53 from murine MC38 colon adenocarcinoma. Deletion of Trp53 and PD-1 ICB synergistically inhibits tumor growth. Il33 is upregulated in the Trp53-deficient and treated tumor cells, and its expression increases with time and response to treatment. Cd4+ and Cd8+ T cell infiltration increases adjacent to IL-33 expressing tumor cells, while Treg infiltration is decreased. Simultaneous deletion of Il33 in MC38 tumors reverses the efficacy PD-1 ICB. Trp53-deficient MC38 in ST2-/- (IL-33 receptor) mice also show no response to PD-1 ICB. Our findings depict a novel mechanism by which the loss of p53 in tumors treated with ICB unleashes the expression of tumoral IL-33 and induces downstream signaling. p53 mutations may be a double-edged sword for cancer, i.e. the loss of the tumor suppressor initially facilitates tumorigenesis, but eventual buildup of mutations and activation of damage pathways, such as NF-kB, leads to upregulation of danger signals in the tumor. These danger signals, such as IL-33, mediate the anti-tumor effect of ICB. Citation Format: David Shihong Gao, Yang Li, Jason Shoush, Runzi Sun, Binfeng Lu. Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1326.

10 December 2025
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Effects of MRTX1133 in KPC/Y and subcutaneous models

10 December 2025
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
MRTX1133 elicits changes in the tumor stroma and vasculature

10 December 2025
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Supplementary Figures and Table with legend arranged in a single presentable package